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Abstract
Background: In Japan and other societies with rapidly aging populations, recurrent pneumonia (RP) is a major
clinical problem yet only limited information exists regarding the burden of this disease.
Methods: A prospective study of adult pneumonia was conducted to investigate the incidence of RP and potential
risk factors. From February 1, 2012 to January 31, 2013, patients aged ≥ 15 years who were diagnosed with
pneumonia were prospectively enrolled in a representative community hospital located in central Japan. Patients
were followed for one-year to evaluate the recurrence of pneumonia and characteristics associated with RP. Cox
proportional hazards models were constructed to compute adjusted hazard ratios (aHR) and ascertain risk factors
significantly associated with RP.
Results: In total, 841 patients with a median age of 73 years (range 15–101 years) were enrolled totaling 1,048
person-years of observation with a median follow-up time of 475 days. A total of 137 patients had at least one
recurrent episode with an incidence rate of 13.1 per 100 person-years (95% confidence interval: 11.1–15.5). In
multivariate analysis, a past history of pneumonia (aHR 1.95, 95% CI: 1.35–2.8), chronic pulmonary disease (aHR 1.86,
1.24–2.78) and inhaled corticosteroid usage (aHR 1.78, 1.12–2.84) and hypnotic/sedative medication usage (aHR 2.06,
1.28–3.31) were identified as independent risk factors for recurrent pneumonia, whereas angiotensin converting
enzyme-inhibitors usage was associated with a reduction of the risk of RP (aHR 0.22, 0.05–0.91). The detection of P.
aeruginosa was significantly associated with RP even after adjusting for chronic pulmonary diseases (aHR = 2.37).
Conclusions: Recurrent pneumonia constitutes a considerable proportion of the pneumonia burden in Japan. A
past history of pneumonia, chronic pulmonary disease, inhaled corticosteroid and hypnotic/sedative medication
usage and detection of P. aeruginosa were identified as independent risk factors for recurrent pneumonia and
special attention regarding the use of medications in this vulnerable population is needed to reduce the impact of
this disease in aging populations.
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Background
Pneumonia is one of the most common infectious
diseases and is now the third leading cause of death in
Japan [1]. As populations age, the pneumonia burden is
forecasted to increase further [2, 3]. In adults, a prior
episode of pneumonia is a major risk for subsequent
hospital admissions due to pneumonia [4, 5]. Although
several studies have investigated recurrent pneumonia
(RP), previous investigations have been limited by
methods for data analysis. In addition, previous studies
report little experience from Asia, including Japan, which
has one of the oldest populations in the world [4, 6–9].
In 2004, a prospective cohort study was used to iden-
tify several risk factors for community -acquired pneu-
monia (CAP) [2]. In addition to older age and a past
history of pneumonia, this study found that male gender,
smoking, increased alcohol intake as well as co-morbid
health conditions such as chronic obstructive pulmonary
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disease (COPD), lung cancer, chronic heart disease,
diabetes mellitus, and a history of stroke were associated
with CAP [2]. Recently, studies have focused on potentially
modifiable medication-associated risk factors including the
use of inhaled corticosteroids, acid-suppressing drugs, and
angiotensin converting enzyme-inhibitors (ACE-I) [10–12].
However, a limited number of studies have investigated risk
factors for RP [6–9]. To reduce the burden of pneumonia,
the identification of modifiable risk factors for RP would
aid clinicians in the evaluation and management of patients
with pneumonia and help guide programs designed to
prevent pneumonia among adults in an aging population.
To reveal disease burden of total adult pneumonia in
Japan, we have previously conducted a multi-center pro-
spective study, called Adult Pneumonia Study Group –
Japan (APSG-J) [3]. The current study is a sub-analysis of
APSG-J study with the goal of describing the incidence of
RP in Japanese adults and identifying the risk factors asso-
ciated with pneumonia recurrence.
Methods
Study design and patient population
In the context of the APSG-J [3], we conducted sub-
analysis of data with further collecting data pertaining to
RP from a sub-group of patients as follows. The APSG-J
study enrolled adult patients aged ≥ 15 years with
physician-diagnosed pneumonia, including pneumonia
managed as outpatients, at four community hospitals on
four major islands in Japan. In the current study tar-
geting RP, a hospital-based cohort was established at
Kameda General Hospital, the largest hospital in the
APSG-J with 865 beds and 458 clinicians. Kameda
General Hospital provides not only primary medical
care but also functions as the sole provider of tertiary
medical care for residents in Kamogawa city and the
surrounding towns in Chiba Prefecture, Central Japan;
31.1% of the referral population were older than
65 years according to the national population census.
All residents have good access to hospital care under
the universal health coverage. It was assumed that pa-
tients registered at the hospital would return if they
became ill again.
Patients who visited Kameda General Hospital be-
tween February 1, 2012 and January 31, 2013 were
followed prospectively until January 31, 2014 to identify
cases of RP. A research clinician independently reviewed
medical records of patients diagnosed with pneumonia
and conducted an independent review of patients’ thor-
acic diagnostic images and results (i.e., routine chest
radiographs and chest computed tomography [CT]
scans). For cases in which a diagnostic discrepancy was
found between hospital physicians and the research clin-
ician, the final diagnosis of pneumonia was made by an
experienced respiratory consultant. In the original multi-
center study, the APSG-J research protocol enrolled
patients using the following exclusion criteria: hos-
pital-acquired pneumonia (HAP), pneumonia other
than acute infectious pneumonia (i.e., interstitial
pneumonia, pulmonary tuberculosis, nontuberculous
mycobacterial infection, pneumocystis pneumonia, or
drowning). To address RP among patients who recov-
ered from the latest pneumonia event, the current
study excluded patients who died in the hospital at
first enrolment and patients who experienced an epi-
sode of pneumonia within 30 days of the last treat-
ment. We assumed our patient population was less
influenced by treatment variables for pneumonia at
the entry.
The study was conducted in accordance with the
Guidelines for Ethical Aspects in Epidemiological
Studies (Ministry of Health, Labor and Welfare, 2008)
and was approved by the independent research ethics
committees of the Institute of Tropical Medicine,
Nagasaki University (Nagasaki, Japan) and Kameda
General Hospital [3]. Written informed consent was
obtained from the majority of the participants or their
guardians. The requirement for obtaining written con-
sent from all participants was waived by all independ-
ent research ethics committees because of the study’s
observational nature without any deviation from the
current medical practice.
Data collection
To identify eligible RP episodes, we selected only the
first qualifying event for each patient. Basic demo-
graphic, clinical and laboratory data were prospectively
collected at first enrolment by hospital physicians and a
research clinician. Variables included age, sex, Eastern
Cooperative Oncology Group (ECOG) performance
status (PS), co-morbid illnesses (e.g., diabetes mellitus,
congestive heart failure, ischemic heart disease, chronic
liver disease, chronic renal disease, collagen-vascular
disease, dementia, malignancy, bronchial asthma, tuber-
culosis, and chronic obstructive pulmonary disease),
medications (e.g., oral corticosteroids, inhaled corticoste-
roids, immunosuppressants, ACE-Is, biological products,
anti-neoplastic drugs, acid-suppressing drugs, antipsychotic
drugs, hypnotics and sedatives), and immunization status
[2, 13–16]. In addition, information regarding smoking sta-
tus, alcohol intake, past history of pneumonia, as well as
risk factors for aspiration, including episodes of aspiration,
dysphagia, consciousness disturbances, neuromuscular dis-
eases, cerebrovascular diseases, tube feeding, and pro-
tracted bedridden status [2, 14, 17]. We also collected
information at the first visit to categorize pneumonia epi-
sodes into two categories: CAP and healthcare-associated
pneumonia (HCAP) according to the definition of the
ATS/IDSA guidelines [18, 19]. The severity of pneumonia
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at presentation was measured using the CURB scoring sys-
tem [20, 21].
Microbiological tests
Bacteriological testing of clinical sputum and blood
specimens was performed using standard microbio-
logical procedures. Streptococcus pneumoniae antigen in
the urine was detected using a rapid immunochromato-
graphic assay (BinaxNOW™ Streptococcus pneumoniae;
Alere Inc, Waltham, MA, USA).
Statistical methods
Rates of recurrent pneumonia (expressed per 100
person-years of observation) were computed from the
date of enrolment until the date of the hospital admis-
sion for recurrent pneumonia or the end of follow-up
(i.e., January 31, 2014), whichever came first. Because
Kameda General Hospital services as the sole provider
of tertiary care to Kamogawa City residents, we identi-
fied the hospital catchment area population based on
census data for Kamogawa City (35,766 total residents;
according to National Population Census in 2010).
Participants who died due to any cause after the enrol-
ment were treated as censored at the date of death. Cox
proportional hazards models were applied to quantify
the hazard ratios and the 95% confidence intervals (CI)
for RP. The multivariate analysis of risk factors associ-
ated with RP included all significant variables identified
in the univariate analysis considered to be clinically rele-
vant. In detail, we included following factors in multi-
variate analysis: male, age group, HCAP, past pneumonia
history, albumin, performance status, diabetes mellitus,
ischemic heart diseases, collagen disease, dementia, lung
cancer, chronic pulmonary diseases, aspiration risk
factor, oral corticosteroids, inhaled corticosteroids, im-
munosuppressants, ACE-Is, statins, biological products,
anticancer drugs, acid-suppressing drugs, antipsychotic
drugs, hypnotics and sedatives, and other drugs. The
microbiological test results were compared between
patients with and without RP using a chi-square test or
Fisher’s exact test. Statistical tests were conducted with
STATA version 12.0 (Stata Corp., College Station, TX,
USA). All tests were performed in a two-tailed manner,
and statistical significance was determined at the 5% level.
Results
Patient characteristics
During the study recruitment period, a total of 1,128
patients were considered for enrolment at the study
hospital. A total of 287 patients were excluded (231
patients did not meet the inclusion criteria and 56 pa-
tients died during the first pneumonia episode) leaving
841 patients eligible for inclusion in the study analysis.
The demographic features of patients at first enrolment
are summarized in Table 1. The median age was 73 years
(range 15–101 years), and a considerable proportion
(47%) of patients were ≥ 75 years old. Over half (54%) of
the patients were hospitalized, and 20% had HCAP. A
quarter of patients had a previous history of pneumonia.
A considerable proportion of patients were under nour-
ished with a body mass index (BMI) < 18 kg/m2 and/or a
low serum albumin level (Alb) of < 3.5 g/dl. The PS was
available for 542 patients; 139 (26%) of these patients
(16.5% of all patients) did not have fully independent
functional status (PS ≥ 2). Approximately one-quarter of
pneumonia cases were classified with a CURB score ≥ 2
[20] The majority (74%) of patients had at least one co-
morbidity that was potentially associated with pneumonia;
the most frequent co-morbidity was chronic obstructive
pulmonary disease, followed by diabetes mellitus and
malignancy. One-third of the patients were found to have
some aspiration risk. Nearly half (48%) of patients were
taking medications potentially associated with pneumonia.
The most frequently used medications were acid-
suppressing drugs, followed by statins, inhaled corticoste-
roids, oral corticosteroids, and hypnotics.
Incidence of recurrent pneumonia
Over the entire duration of follow-up, a total of 98 deaths
were identified among the study patients. Consequently, a
total of 1,048 person-years of observations were made with
a median follow-up time of 475 (interquartile range, IQR:
380–595) days. During the follow-up period, 137 (16.3%)
patients developed RP. The incidence rate of recurrence
was 13.1 (95% CI: 11.1–15.5) per 100 person-years. The
median time to recurrence was 196 (IQR: 104–339) days,
and 82% of episodes occurred within 1 year of presenta-
tion. Forty-nine (36%) patients had more than one recur-
rence. We estimated the incidence rate by limiting the
study patients to only residents of Kamogawa City, the site
where the study hospital is located. The incidence rate of
RP was slightly higher, 14.8 (95% CI, 11.3–19.3) per 100
person-years.
Characteristics of patients who developed recurrent
pneumonia
The clinical presentations at first enrolment were com-
pared between 137 patients who developed RP and 704
patients who did not develop pneumonia. The frequencies
of each symptom were similar, and the severity of RP was
similar to the severity of the first episode; the proportion
of severe pneumonia (CURB ≥ 2) was 24.7% [20]. The
duration of treatment was 8 days as median in both
groups with RP (3–38 days) and without RP (1–66 days).
Risk factors for development of recurrent pneumonia
Table 1 summarizes the results of the risk factor analysis.
In the univariate analysis, we found that patients with
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Table 1 Characteristics of study patients and risk factors for recurrent pneumonia; Cox proportional hazard analysis
Characteristic Subgroup n (%) Crude HR 95% CI P > z Adjusted HRd 95% CI P > z
Male 467 (55.5) 1.27 0.9 1.79 0.167 1.08 0.73 1.59 0.696
Age group (years old) 15–49 137 (16.3) Ref.
50–74 308 (36.6) 3.71 1.58 8.69 0.003 2.04 0.84 4.99 0.116
≥75 396 (47.1) 6.29 2.75 14.4 <0.001 2.6 1.06 6.43 0.038
HCAP 164 (19.5) 2.05 1.41 2.98 <0.001 1.45 0.92 2.31 0.112
Past Pneumonia Historya 218 (25.9) 2.86 2.04 4 <0.001 1.95 1.35 2.8 <0.001
Albumin (g/dl) <3.5 330 (39.2) 1.74 1.23 2.45 0.002
Unknown 83 (9.9) 0.39 0.16 0.97 0.042
Body Mass Index <18 120 (14.3) 1.82 1.19 2.79 0.006 1.41 0.89 2.23 0.14
Unknown 221 (26.3) 0.77 0.5 1.19 0.24 0.9 0.57 1.41 0.64
Performance Status ≧2 139 (16.5) 1.97 1.29 3.01 0.002 1.08 0.62 1.9 0.787
Unknown 299 (35.6) 0.9 0.61 1.33 0.594 0.66 0.42 1.03 0.067
CURB 0 292 (34.7) Ref.
1 301 (35.8) 0.99 0.67 1.46 0.942
≧2 208 (24.7) 1.07 0.7 1.65 0.752
Unknown 40 (4.8) 0.26 0.06 1.08 0.063
Comorbidities Diabetes Mellitus 153 (18.2) 1.42 0.95 2.12 0.085 1.39 0.89 2.18 0.149
Heart Failure 88 (10.5) 0.79 0.43 1.47 0.46
Ischemic Heart Diseases 42 (5.0) 2.05 1.13 3.71 0.017 1.18 0.61 2.29 0.616
Collagen Diseases 66 (7.9) 2.16 1.33 3.5 0.002 1.57 0.69 3.56 0.282
Dementia 62 (7.4) 1.59 0.91 2.76 0.1 1.29 0.68 2.43 0.431
Malignancy without Lung Cancerb 130 (15.5) 1.02 0.64 1.64 0.929
Lung Cancer 21 (2.5) 2.36 1.04 5.35 0.04 2.63 1.09 6.34 0.031
Bronchial Asthma 82 (9.8) 1 0.57 1.74 0.998
Tuberculosis 30 (3.6) 0.57 0.18 1.8 0.343
Chronic Pulmonary Diseases 173 (20.6) 2.83 2.01 3.98 <0.001 1.86 1.24 2.78 0.003
Others 480 (57.1) 1.23 0.87 1.73 0.246
Aspiration Risk Factor 236 (28.1) 1.66 1.17 2.36 0.004 1.01 0.65 1.58 0.958
Medication Oral Corticosteroids 76 (9.0) 2.14 1.33 3.44 0.002 1.48 0.74 2.96 0.263
Inhaled Corticosteroids 86 (10.2) 2.57 1.71 3.88 <0.001 1.78 1.12 2.84 0.015
Immunosuppressants 27 (3.2) 2 0.98 4.1 0.056 1.3 0.5 3.36 0.591
ACE-Ic 37 (4.4) 0.31 0.08 1.25 0.1 0.22 0.05 0.91 0.037
Statins 114 (13.6) 0.97 0.59 1.6 0.919 0.95 0.57 1.6 0.854
Biological Products 11 (1.3) 2.44 0.9 6.61 0.078 1.99 0.62 6.37 0.247
Anticancer Drugs 29 (3.5) 0.39 0.1 1.58 0.186 0.41 0.1 1.7 0.221
Acid-Suppressing Drugs 235 (27.9) 1.41 0.99 2.02 0.059 0.97 0.64 1.48 0.893
Antipsychotic Drugs 44 (5.2) 1.85 1.02 3.35 0.041 1.74 0.91 3.35 0.096
Hypnotics and Sedatives 70 (8.3) 2.81 1.81 4.37 <0.001 2.06 1.28 3.31 0.003
Others 498 (59.2) 1.49 1.04 2.12 0.029 1.23 0.82 1.85 0.311
HR hazard ratio; CI confidence interval
a14 patients whose past pneumonia history was not available were assumed to not have a past pneumonia history
bMalignancy was defined as a history of cancer or active cancer
cAngiotensin converting enzyme inhibitor
dHRs were adjusted for all other variables
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older age, HCAP, a past pneumonia history, underweight
status and fully independent functional status were sig-
nificantly more likely to have experienced RP (P < 0.05).
When adjusted for gender, age group, past pneumonia
history, aspiration risk, co-morbidities and medica-
tions, the association with HCAP, low BMI and high
PS was no longer present. The severity of pneumonia
measured by the CURB score at study enrolment was
not associated with RP.
Our univariate analysis showed that several co-
morbidities increased the crude risk of RP. Of these, the
risk was greatest for patients with pre-existing chronic
pulmonary diseases (OR, 2.83; 95% CI: 2.01–3.98) followed
by lung cancer, collagen-vascular disease and ischemic
heart diseases. However, in the multivariate analysis, the
risk of most of these co-morbidities disappeared, except for
lung cancer (OR, 2.63; 95% CI, 1.09–6.34) and chronic
pulmonary diseases (OR, 1.86; 95% CI, 1.24–2.78) which
included both COPD and bronchiectasis. In multivariate
analysis, patients receiving inhaled corticosteroids (OR,
1.78; 95% CI, 1.12–2.84), antipsychotic drugs (OR, 1.74;
95% CI: 0.91–3.35) and hypnotics/sedatives (OR, 2.06; 95%
CI, 1.28–3.31) were more likely to have experienced RP.
Interestingly, patients taking ACE-Is were significantly less
likely to develop RP (OR, 0.22; 95% CI, 0.05–0.91). The use
of statins was not associated with a reduction of pneumonia
recurrence in either the univariate or multivariate analyses.
In univariate analysis, aspiration increased the risk of
RP but this association did not persist in the multivariate
analysis. We found that age, HCAP, a past pneumonia
history and PS were confounding variables for aspiration
risk. We also analyzed the lifestyle risk factors of current
smoking, alcohol intake, contact with pets, contact with
dust, frequent contact with children (≤5 years), frequent
contact with the elderly (≥65 years), the number of indi-
viduals in the home, familial history of pneumonia and
history of travel within 3 months. However, none of
these factors exhibited any significant association with
RP (data not shown). The immunization history against
influenza and pneumococcus was available only in 53.8%
of patients; therefore, this factor was not included in the
current model.
Kaplan-Meier survival curves depicting the recurrence
of pneumonia in relation to the identified risk factors
are shown in Additional file 1: Fig. S1. The survival
curves did not differ between the age groups of 50–64
and 65–74 years; therefore, in this analysis, these age
groups were combined (data not shown).
Aetiology
Table 2 shows the frequency of bacteria isolated from
sputum cultures. A sputum culture was performed in
736 (88%) patients at first enrolment. The most fre-
quently isolated organism was Haemophilus influenzae,
although when the results of the urine antigen tests were
combined, the frequency of S. pneumoniae was similar
to that of H. influenzae. We compared the bacterial
isolates at the first enrolment of 130 patients who devel-
oped RP with the remaining 606 patients. Although the
distribution of isolated bacteria was similar in both
groups, the frequency of Pseudomonas aeruginosa and
gram negative rods was significantly higher in the patients
with RP. The detection of P. aeruginosa was strongly asso-
ciated with chronic pulmonary diseases (P < 0.001), and
the association of P. aeruginosa with RP remained signifi-
cant even after adjusting for chronic pulmonary diseases
(Hazard Ratio = 2.37, P = 0.001).
Survival prognosis of patients with recurrent pneumonia
Among the 137 patients who developed recurrent pneu-
monia, 5 patients died during the recurrent episode, and
49 patients experienced another episode of RP. We con-
firmed a total of 98 deaths at the end of the observation
period, of which only 13 patients died during the course
of a hospital re-admission for RP. Patients with RP were
significantly more likely to have fatal outcomes than
patients without RP (Hazard Ratio = 2.81, P < 0.001).
Figure 1 shows the Kaplan-Meyer survival curves.
Discussion
High burden of recurrent pneumonia in Japan
This is the first study demonstrating that RP constitutes
a considerable proportion of the pneumonia burden in
Japan. One in four pneumonia patients had a past
history of pneumonia at study enrolment, and 16% of
patients developed RP during the follow-up period of
less than two years. This RP rate is higher than the
figures of 9.4–12% recently reported in published studies
that followed CAP patients for 3–5 years [6, 7]. The
higher rate in the present study may have occurred
because our study population included more vulnerable
individuals, such as elderly subjects, and because we
prospectively identified relatively mild pneumonia cases
treated in outpatients.
Risk factors for recurrent pneumonia
The risk factor analysis revealed that in addition to age
(≥75 years old), a past pneumonia history, lung cancer,
chronic pulmonary diseases, and the administration of
inhaled corticosteroids and hypnotics increased the risk
of RP. Of these risk factors, a past history of pneumonia
was particularly influential because the significant asso-
ciation with HCAP, PS and BMI in the univariate
analysis was not present when a past history of pneumo-
nia was integrated into the multivariate model. This
strong association with a past history of pneumonia indi-
cates that pneumonia is a reflection of a frail condition
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and the aggregate of many risk factors of contracting
pneumonia.
The risk factors for RP closely overlap but are not iden-
tical to risk factors for contracting pneumonia. As Dang,
et al. discussed in their paper on RP [7], the selection of
the study population on the basis of previous occurrence
of pneumonia has potential for introducing bias referred
to as index event bias [22]. Due to this type of bias, previ-
ously determined risk factors for developing pneumonia,
such as aspiration risk [23] and systemic corticosteroid
use [24], became less frequently associated with RP.
Nevertheless, we believe our risk factor analysis provides a
robust multivariate analysis of factors that many clinicians
will encounter in their daily practice and provide useful
information to clinicians who diagnose pneumonia.
In our analysis, medications represent important,
potentially modifiable risk factors for RP. Our study
showed that the use of hypnotics was independently asso-
ciated with RP. Although the association between
benzodiazepines and the risk of contracting pneumonia is
controversial [25–28], El Solh et al. showed that tranquil-
izers were a risk factor for recurrent hospitalization for
pneumonia among individuals older than 65 years [29],
and Dang et al. also reported a tendency of RP in patients
using sedative-hypnotics. These findings are consistent
with our analysis. Short-acting benzodiazepines or non-
benzodiazepine hypnotics are frequently prescribed for
elderly patients in Japan [30, 31]. Thus, increased con-
sumption of benzodiazepine sedative-hypnotics may be
contributing to the high incidence of RP among elderly
Japanese.
Our results are consistent with previous studies [32, 33]
showing the use of an inhaled corticosteroids may pose a
risk for RP even after adjustment for age and chronic
pulmonary diseases. At the same time, we recognize that
these drugs consistently decrease COPD exacerbations
and improve the quality of life [34, 35] and thus, choices
and recommendations regarding the use of inhaled corti-
costeroids pose a clinical dilemma. These findings suggest
that prescribing of inhaled corticosteroids for COPD
patients requires special attention when patients have an
episode of pneumonia [36].
Our results also indicate that the use of ACE-Is
reduce the risk of RP. This finding is consistent with
the results of previous papers [7, 29]. ACE-Is have been
found to protect against pneumonia, especially among
Asians [12, 37]. The protective effects against aspiration
by ACE-Is through increasing substance P might be-
come more apparent among a population with dyspha-
gia or silent aspiration, such as our study population.
These findings are particularly important for elderly
patients suffering from hypertension and other cardio-
vascular diseases such as congestive heart failure who
may be taking ACE-Is on a regular basis.
Table 2 Bacterial pathogens identified by sputum culture and urinary antigen tests
All Patients without recurrent pneumonia Patients with recurrent pneumonia
n = 736 % n = 606 % n = 130 % P-value
Streptococcus pneumoniae 96 13.04 75 12.38 21 16.15 0.246
Haemophilus influenzae 119 16.17 101 16.67 18 13.85 0.428
Moraxella catarrhalis 60 8.15 46 7.59 14 10.77 0.229
Staphylococcus aureus 59 8.02 43 7.1 16 12.31 0.047
Gram-negative bacilli 100 13.59 73 12.05 27 20.77 0.008
Pseudomonas aeruginosa 48 6.52 31 5.12 17 13.08 0.001
Klebsiella pneumoniae 29 3.94 20 3.3 9 6.92 0.054
Escherichia coli 14 1.9 11 1.82 3 2.31 0.709
Enterobacter species 9 1.22 8 1.32 1 0.77 0.604
Other GNB 12 1.63 10 1.65 2 1.54 0.927
Others 212 28.8 185 30.53 27 20.77 0.026
S. pneumoniae (Culture + Urine Antigen) 124 16.78 100 16.42 24 18.46 0.572
Percentages total more than 100% due to multiple culture results
Fig. 1 Kaplan-Maier survival curve according to presence of
recurrent pneumonia. Patients with recurrent pneumonia were
significantly more likely to have fatal outcomes than patients
without recurrent pneumonia (Hazard Ratio = 2.81, P < 0.001)
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Eurich, et al. reported that acid-suppressing drugs
increased RP during a follow-up period of 5 years [38]
but we found no such association after adjustment for
age. This discrepant result might be due to that our ob-
servation period, a maximum of two years, was too short
to demonstrate the effect and that the previous study
excluded subjects < 65 years, which were included in our
study. Furthermore, another case–control study showed
the association of pneumonia was only with proton
pump inhibitors but not H2-blockers [39]. Our study
could not dissociate the type of acid-suppressing drugs.
Etiologic agents in recurrent pneumonia
P. aeruginosa was the only cultured pathogen that was
significantly associated with pneumonia recurrence.
Because we defined all culture positive results as P. aeru-
ginosa positive cases regardless of patient conditions or
bacterial loads, the isolation of P. aeruginosa does not
necessarily represent infection but could represent
colonization. However, in the present study, this associ-
ation remained significant even after adjustment for all
possible risk factors, including chronic pulmonary dis-
eases. Furthermore, the tendency did not change when
we re-classified P. aeruginosa positive cases, taking into
account the quality of sputum and/or the bacterial load
and re-analysed the data. This finding suggests the possi-
bility that P. aeruginosa plays a role in the pathogenesis
of RP. This may suggest that infection/colonization by P.
aeruginosa play a significant role in the evolution of lung
diseases perhaps by interfering the lung microbiome
[40]. In addition, patients who are at increased risk for
P. aeruginosa colonization or infection might also have
underlying defects in local immune or mechanical bar-
rier functions, which we did not explore [41]. Gram
negative rods were more frequently detected in RP, prob-
ably because the risk factors with RP overlap with risk
factors of having gram negative rods, such as high age,
low performance status with aspiration risk [23, 42, 43]
and chronic pulmonary diseases [43]. The corresponding
rate of sputum culture based S. pneumoniae was 13.0%
for all patients and 16.5% for RP group (Table 2), which
are low but compatible with our previous report [3].
Furthermore detection rate of pneumococcus would be
higher with PCR. These findings of etiology pattern may
reflect the nature of pneumonia in an aging population.
Limitations
Our study has several limitations. First, to estimate the
incidence of RP, we assumed that patients registered at
the Kameda General Hospital would visit the hospital if
they became ill again and seek for treatment because
they have good access to hospital-case with same self-
pay as the General Practitioner under the universal
health coverage; otherwise, they were considered as alive
on the census day. However, if frail patients did not seek
hospital treatment and died of RP outside Kameda
General Hospital, these number were not captured in
the outcome analysis. We also excluded patients who
died at first enrolment because one of objectives of the
study is to clarify the risk factors for RP after appropriate
treatment. Therefore, our estimation of the incidence
rate and mortality might be underestimated, but the
disease burden of RP shown here is still high. Second,
this study was analysed using data from a single centre.
Third, data were missing from several variables in the
current study, despite the baseline APSG-J study was
conducted in a prospective manner. This was because
these variables were not included in the original APSG-J
study design thus it required retrospective data collec-
tion through medical chart review. Fourth, unmeasured
confounding factors (including demographic characteris-
tics such as socioeconomic status or clinical characteris-
tics and treatment variables such as ICU admission, type
of antibiotics) could influence our findings.
Conclusion
In summary, the present study showed the substantially
high disease burden of RP and several independent
factors associated with RP, including some medications
such as hypnotics, inhaled corticosteroids and ACE-Is,
and P. aeruginosa infection/colonization. We believe
that knowledge of these risk factors might be useful for
identifying high risk groups and taking measures to
prevent repetitive attacks of pneumonia.
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